Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of MR13A9 in hemodialysis patients with uremic pruritus
jRCT2011200021Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease-associated pruritus (CKD-aP) comparing MR13A9 0.5 μg/kg with Placebo (2 arms). Primary endpoint: Change from baseline in mean itch NRS score at week 4. Started Jan 2021; status: completed.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on jRCT2011200021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200021.